Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

177 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-11-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to discover modifiable risk factors for the development of neuropathy, specifically looking at the metabolic syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy

NCT01565317

Diabetic Polyneuropathy Weight Loss

COMPLETED NA

Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome

NCT00907127

Metabolic Syndrome

COMPLETED PHASE1

Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study

NCT01465620

Peripheral Nervous System Diseases Diabetic Polyneuropathy Metabolic Syndrome X

COMPLETED PHASE3

Fall Risk Assessment in People With Diabetic Neuropathy

NCT01040962

Diabetic Peripheral Neuropathy

COMPLETED

Pain In Neuropathy Study

NCT02672059

Diabetic Neuropathy Neuropathic Pain Chronic Pain +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators propose to follow obese individuals and determine the impact of the aspects of the metabolic syndrome on the incidence of neuropathy compared to lean individuals.

While there are many well established relationships between obesity and disease, the association of obesity and the metabolic syndrome with peripheral neuropathy is less clear.

The investigators will be following a population of 300 adult individuals age 18 years or older with obesity and 300 adult individuals without obesity or any aspect of the metabolic syndrome (hyperlipidemia, hypertriglyceridemia, hypertension, hyperglycemia, obesity). Obese subjects will be recruited through the Investigational Weight Management Clinic. A proportion of the subjects will be recruited through Blue Care Network of Michigan (BCN) as part of their Healthy Blue Living campaign which is supporting clinical care of up to 400 individuals in the clinic. The individuals not recruited directly through the clinic will be identified via flyer, word of mouth, and umclinicalstudies.org.

The phenotyping information for the obese subjects will be already completed as part of the initial project. Lean subjects will undergo screening for eligibility, which includes taking height, weight, blood pressure, lipid profile, and glucose tolerance test.

Neuropathy measures completed at baseline and 2 years (obese subjects only) include: definite clinical neuropathy will be established using Toronto consensus guidelines based upon neurologic exam, nerve conduction studies, Michigan Neuropathy-Specific Instrument, Utah Early Neuropathy Scale, balance and hip strength measures, cognitive testing (computerized cognitive screening to determine how obesity affects the central nervous system) (also done at time 12 +/- 4 weeks and 52 +/- 4 weeks post-baseline visit), neurothesiometer testing, skin biopsy to determine nerve fiber density, Quantitative Sudomotor Axon Reflex Test (QSART) to measures the autonomic nerves that control sweating, heart rate variability/cardiac autonomic neuropathy testing to assess for autonomic neuropathy, quantitative sensory testing to assess for small fiber neuropathy, Sudoscan to assess sweat gland function, and the following questionnaires: Neuropathy Quality of Life, McGill Pain, Autonomic symptoms profile.

The investigators intend to demonstrate that obesity and other aspects of the metabolic syndrome have a direct impact on the incidence of peripheral neuropathy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Obesity Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese participants

Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.

No interventions assigned to this group

Lean participants

Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age over 18
2. Willing and able to provide written informed consent, enrolled in the Investigational Weight Management Clinic at the University of Michigan

Exclusion Criteria

1. Taking blood thinning medications, except aspirin, Evidence of inherited disorders of lipid metabolism
2. History of cancer within the last 5 years
3. Human immunodeficiency virus (HIV) antibody positive
4. Subjects with solid organ transplants
5. Participation in any other clinical trial within 90 days of entry into this trial
6. Pregnant or lactating females
7. Uncontrolled thyroid disease
8. Unstable angina or New York heart association class II failure or above
9. Gastrointestinal disease specifically gastrointestinal motility disorders
10. Unstable neuropsychiatric disease including major depression/anxiety, bulimia, or anorexia
11. End stage renal or hepatic disease
12. Autoimmune disorders (e.g. lupus)
13. Body weight fluctuation of more than 5 kg in the previous 3 months
14. Prior bariatric surgery
15. A history or current substance abuse, change in smoking habits, or cessation in the past 6 months
16. Women of childbearing age must use a reliable form of contraception
17. Any medical condition, which would make the patient unsuitable for recruitment, or could interfere with the patient participating in or completing the protocol

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes